Novartis Heart Drug Gets Endorsed by NICE, But Not for EveryoneBy
Entresto backed for about 100,000 people with heart failure
Patients must first take hypertension drugs, NICE rules
A Novartis AG heart drug that’s struggled to gain acceptance in the U.S. won the backing of a U.K. panel as a cost-effective treatment, even without a price discount.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.